A Phase 2 trial in Barcelona, Spain, showed that adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and chemotherapy improved responses for certain patients with lung cancer. The trial tested Opdualag, a combination of Bristol’s Opdivo and relatlimab, targeting a checkpoint called LAG-3. While Opdualag is approved for advanced melanoma, it had failed in some colorectal and liver cancer indications. The new study tested relatlimab with Opdivo and chemotherapy compared to Opdivo and chemotherapy alone in advanced non-small cell lung cancer. The goal was to determine which patients benefited from adding the anti-LAG-3 drug to the treatment regimen.
Source link
Bristol immunotherapy hits in lung cancer, advancing to Phase 3
